Market research
OXB.LSE Oxford Biomedica plc
LSE GBP Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 616M
- P/E ratio
- Not available
- Analyst target
- 712
- Dividend yield
- Not available
- Beta
- 1.1
Profile
Company facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- GB00BDFBVT43
- Market cap
- 616M
- P/E ratio
- Not available
- Analyst target
- 712
- Dividend yield
- Not available
- Beta
- 1.1
About
About Oxford Biomedica plc
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems; InAAVate, a proprietary "plug and play' dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the OXB.LSE discussion.
5 years, 4 months ago
Oxford Biomedica plc is currently in a long term uptrend where the price is trading 37.9% above its 200 day moving average.
From a valuation standpoint, the stock is 97.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 11.1.
Based on the above factors, Oxford Biomedica plc gets an overall score of 2/5.